ProBiotix Health enters a commercial partnership with Greece-based Eifron SA
ProBiotix Health, a life sciences business developing probiotics to support cardiometabolic health, has entered a commercial partnership with Greece-based consumer brands specialist, Eifron SA.
As part of the deal, Eifron will introduce YourBiotixBP tablets, containing ProBiotix’s product LPLDL®, under its existing probiotic consumer brand, with the anticipated product launch expected to be in quarter one 2025.
Through this partnership, Eifron will expand its own portfolio by including a product for cholesterol and blood pressure lowering based on LPLDL®.
The addition of other products from the ProBiotix portfolio will be evaluated by the parties on an ongoing basis.
ProBiotix Health has received a purchase order from Eifron, with the first sales planned for Greece and afterwards in selected regions in Europe.
Founded in 2011, Eifron specialises in healthcare solutions. In Greece it is among the top five brands in the country.
Its core focus is addressing unmet medical needs by developing and distributing advanced product solutions for the health sector, with particularly close ties among pharmacies and healthcare professionals. The current Eifron product portfolio includes pharmaceuticals, supplements, and medical devices.
Steen Andersen, CEO of Wakefield-based ProBiotix, said: “This exceptional opportunity to work with a science driven market leader like Eifron represents another significant milestone in our efforts to expand our reach and broaden the availability of our innovative cardiometabolic health product solutions in Europe."
For more information and the source, visit: City briefs: Kromek; ProBiotix Health; and more | TheBusinessDesk.com